Skip to main content
BioSyent Inc. logo

BioSyent Inc. — Investor Relations & Filings

Ticker · RX ISIN · CA0906901081 TSXV Manufacturing
Open in API
Filings indexed 411 across all filing types
Latest filing 2020-11-05 Regulatory Filings
Country CA Canada
Listing TSXV RX

About BioSyent Inc.

https://www.biosyent.com/

BioSyent Inc. is a profitable, growth-oriented specialty pharmaceutical company focused on enhancing patient lives by addressing unmet medical needs. The company's primary business model involves sourcing, in-licensing, and acquiring innovative pharmaceutical and healthcare products globally for development and commercialization. BioSyent markets a diverse portfolio of products, including prescription, over-the-counter, and behind-the-counter options, primarily serving markets in Canada and select international regions.

Recent filings

Filing Released Lang Actions
News release - French.pdf
Regulatory Filings Classification · 95% confidence The document is a press release announcing the launch of a new pharmaceutical product, FeraMAX Pd Therapeutique 150, by BioSyent Inc. It contains no financial statements, no regulatory filings, no voting results, no management or board changes, no earnings data, and no detailed financial or strategic presentations. It is a product launch announcement intended for immediate dissemination. The document is about a new product introduction and does not fit into any of the specific financial or regulatory filing categories such as Annual Report, Earnings Release, or Capital Update. It is not a report or a regulatory filing but a corporate press release. The closest fitting category from the provided list is Regulatory Filings (RNS) as a fallback for miscellaneous announcements that do not fit other categories.
2020-11-05 English
News release - English.pdf
Regulatory Filings
2020-10-15 English
News release - French.pdf
Regulatory Filings
2020-10-05 English
News release - English.pdf
Regulatory Filings Classification · 95% confidence The document is a press release announcing that BioSyent Inc. has signed an exclusive license and supply agreement for a new women's health product. It discusses the product launch plans and company background but does not contain any financial statements, regulatory filings, or detailed financial data. The document is short (2935 characters) and serves as a corporate announcement about a business agreement rather than a financial report or regulatory filing. It does not fit into categories like Annual Report, Earnings Release, or Capital Update. It is best classified as a Regulatory Filing (RNS) since it is a general corporate announcement that does not fit other specific categories.
2020-10-01 English
52-109FV2 - Certification of interim filings - CFO (E).pdf
Regulatory Filings Classification · 95% confidence The document is a certification form titled 'FORM 52-109FV2' which is a 'Certification of Interim Filings' by the CFO of BioSyent Inc. It certifies the review and fair presentation of interim financial statements and interim MD&A for the period ended June 30, 2020. The document explicitly states it is a certification and does not contain the actual interim financial data or analysis itself. It is a compliance attestation related to interim filings, not the filings themselves. According to the Certification Rule, such officer certifications should be classified as Regulatory Filings (RNS) rather than as the interim report (IR) they reference. The document length is short (2968 characters), consistent with a certification letter rather than a full report.
2020-08-26 English
52-109FV2 - Certification of interim filings - CEO (E).pdf
Regulatory Filings Classification · 100% confidence The document is a certification form titled 'FORM 52-109FV2' which is a 'Certification of Interim Filings' by the CEO of BioSyent Inc. It certifies the review and fair presentation of interim financial statements and interim MD&A for the period ended June 30, 2020. The text explicitly states it is a certification and does not contain the actual interim financial data or analysis, but rather an attestation regarding those filings. According to the Certification Rule, documents that are primarily officer certifications or attestations, even if referencing interim reports, should be classified as Regulatory Filings (RNS) rather than as the interim report itself (IR). The document length is short (2966 characters) and it is clearly a certification form, not the interim report or financial statements themselves.
2020-08-26 English

Browse filings by year

14 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.